FPH reminds shareholders of DRP, amends formula calculation

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Fisher & Paykel Healthcare reminds shareholders of Dividend Reinvestment Plan (DRP),
amends formula for calculation of additional shares

Auckland, New Zealand, 13 June 2023 - Fisher & Paykel Healthcare reminds shareholders of its
Dividend Reinvestment Plan, while also advising of amendments to the formula for calculating a
DRP participant’s entitlement to additional shares.

The DRP was reactivated late last year for eligible shareholders residing in New Zealand, Australia
and the United Kingdom. Under this plan, eligible shareholders may elect to reinvest all of part of
their cash dividends in additional shares at a 3% discount.

Shareholders not previously enrolled who wish to participate in respect of the FY2023 final
dividend will need to opt into the plan via Link Market Services’ website at
https://investorcentre.linkgroup.nz/ or return a physical participation form before 5pm on 28 June
2023.

The company also advises of amendments to the plan to ensure that each participating
shareholder acquires their shares at the same effective price and does not lose any fractional
entitlements to shares as a result of rounding. More specifically, the formula has been amended to:

a) permit the company to round a participant’s entitlement down to the nearest whole share;
and

b) hold the balance of any remaining dividend for the benefit of the participant until the next
time the DRP operates.

An updated version of the DRP offer document setting out the terms and conditions of the plan and
further details of its operation (including how the number of ordinary shares to be issued to each
DRP participant will be calculated) is now available on the company’s website at fphcare.com/drp.

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive
sleep apnea. The company’s products are sold in over 120 countries worldwide. For more
information about the company, visit our website www.fphcare.com.

Media & Investor Contacts:

Hayden Brown
Head of Capital Markets and Investor
Relations
hayden.brown@fphcare.co.nz
+64 27 807 8073
Dan Adolph
Senior Communications and Investor Relations
Manager
daniel.adolph@fphcare.co.nz
+64 22 511 4050

Authorised by Raelene Leonard, General Counsel and Company Secretary.